Cargando…

Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine

Thrombosis and thrombocytopaenia secondary to ChAdOx-1 nCov-19 vaccine is a new phenomenon that usually occurs after the first dose of vaccine. Most of these patients are healthy without any prior history of thromboembolic events or heparin use. Hall marks of this condition include detectable antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Atta, Syed Noman, Othman, Nariman, Babar, Munir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719126/
https://www.ncbi.nlm.nih.gov/pubmed/34969796
http://dx.doi.org/10.1136/bcr-2021-246200
_version_ 1784624873981607936
author Atta, Syed Noman
Othman, Nariman
Babar, Munir
author_facet Atta, Syed Noman
Othman, Nariman
Babar, Munir
author_sort Atta, Syed Noman
collection PubMed
description Thrombosis and thrombocytopaenia secondary to ChAdOx-1 nCov-19 vaccine is a new phenomenon that usually occurs after the first dose of vaccine. Most of these patients are healthy without any prior history of thromboembolic events or heparin use. Hall marks of this condition include detectable antibodies to platelet factor 4 and thrombosis at atypical sites particularly cerebral veins and sinuses mimicking atypical heparin induced thrombocytopaenia. We describe a case of a patient who was diagnosed with this rare condition and treated successfully.
format Online
Article
Text
id pubmed-8719126
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-87191262022-01-12 Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine Atta, Syed Noman Othman, Nariman Babar, Munir BMJ Case Rep Case Report Thrombosis and thrombocytopaenia secondary to ChAdOx-1 nCov-19 vaccine is a new phenomenon that usually occurs after the first dose of vaccine. Most of these patients are healthy without any prior history of thromboembolic events or heparin use. Hall marks of this condition include detectable antibodies to platelet factor 4 and thrombosis at atypical sites particularly cerebral veins and sinuses mimicking atypical heparin induced thrombocytopaenia. We describe a case of a patient who was diagnosed with this rare condition and treated successfully. BMJ Publishing Group 2021-12-30 /pmc/articles/PMC8719126/ /pubmed/34969796 http://dx.doi.org/10.1136/bcr-2021-246200 Text en © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
spellingShingle Case Report
Atta, Syed Noman
Othman, Nariman
Babar, Munir
Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine
title Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine
title_full Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine
title_fullStr Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine
title_full_unstemmed Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine
title_short Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine
title_sort cerebral venous sinus thrombosis secondary to chadox-1 ncov-19 vaccine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719126/
https://www.ncbi.nlm.nih.gov/pubmed/34969796
http://dx.doi.org/10.1136/bcr-2021-246200
work_keys_str_mv AT attasyednoman cerebralvenoussinusthrombosissecondarytochadox1ncov19vaccine
AT othmannariman cerebralvenoussinusthrombosissecondarytochadox1ncov19vaccine
AT babarmunir cerebralvenoussinusthrombosissecondarytochadox1ncov19vaccine